Healthcare provider profile · identity verified

Robert Vincent Kavaler, M.D.

Internal Medicine · PARAMUS, NJ · NPI 1932148913

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	526	171
Amlodipine Besylate	Amlodipine Besylate	383	120
Metoprolol Succinate	Metoprolol Succinate	350	96
Levothyroxine Sodium	Levothyroxine Sodium	304	84
Alprazolam	Alprazolam	288	68
Rosuvastatin Calcium	Rosuvastatin Calcium	231	87
Escitalopram Oxalate	Escitalopram Oxalate	186	55
Metformin Hcl	Metformin Hcl	147	51
Losartan Potassium	Losartan Potassium	139	40
Zolpidem Tartrate	Zolpidem Tartrate	139	32
Meloxicam	Meloxicam	137	73
Lisinopril	Lisinopril	132	40
Montelukast Sodium	Montelukast Sodium	116	31
Lorazepam	Lorazepam	113	36
Omeprazole	Omeprazole	112	39
Pantoprazole Sodium	Pantoprazole Sodium	110	38
Gabapentin	Gabapentin	103	35
Prednisone	Prednisone	103	77
Simvastatin	Simvastatin	99	32
Clonazepam	Clonazepam	77	25
Sertraline Hcl	Sertraline Hcl	76	23
Tamsulosin Hcl	Tamsulosin Hcl	75	23
Azithromycin	Azithromycin	72	60
Duloxetine Hcl	Duloxetine Hcl	70	22
Venlafaxine Hcl Er	Venlafaxine Hcl	68	17
Synthroid	Levothyroxine Sodium	65	16
Tramadol Hcl	Tramadol Hcl	65	18
Hydrochlorothiazide	Hydrochlorothiazide	64	23
Valsartan	Valsartan	58	14
Pravastatin Sodium	Pravastatin Sodium	57	20
Oxycodone Hcl	Oxycodone Hcl	53	suppressed
Clopidogrel	Clopidogrel Bisulfate	52	16
Eliquis	Apixaban	52	15
Fluticasone Propionate	Fluticasone Propionate	52	27
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	52	15
Trazodone Hcl	Trazodone Hcl	46	19
Bupropion Xl	Bupropion Hcl	45	13
Atenolol	Atenolol	41	14
Glimepiride	Glimepiride	40	14
Ozempic	Semaglutide	39	suppressed
Allopurinol	Allopurinol	37	12
Furosemide	Furosemide	37	11
Metformin Hcl Er	Metformin Hcl	37	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	36	11
Irbesartan	Irbesartan	35	13
Celecoxib	Celecoxib	34	11
Jardiance	Empagliflozin	34	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	34	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	33	29
Metoprolol Tartrate	Metoprolol Tartrate	32	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Januvia	Sitagliptin Phosphate	30	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	30	suppressed
Warfarin Sodium	Warfarin Sodium	30	suppressed
Ipratropium Bromide	Ipratropium Bromide	27	14
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	27	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Enalapril Maleate	Enalapril Maleate	26	suppressed
Meclizine Hcl	Meclizine Hcl	26	16
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	26	suppressed
Ramipril	Ramipril	26	suppressed
Temazepam	Temazepam	26	suppressed
Mirtazapine	Mirtazapine	25	11
Baclofen	Baclofen	24	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	24	suppressed
Nebivolol Hcl	Nebivolol Hcl	24	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	15
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	21	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Fentanyl	Fentanyl	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Telmisartan	Telmisartan	21	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	20	20
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	20	suppressed
Potassium Chloride	Potassium Chloride	20	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Bupropion Hcl	Bupropion Hcl	18	suppressed
Carvedilol	Carvedilol	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Paroxetine Hcl	Paroxetine Hcl	18	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	17	12
Finasteride	Finasteride	17	suppressed
Alendronate Sodium	Alendronate Sodium	16	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Diazepam	Diazepam	16	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	16	suppressed
Levofloxacin	Levofloxacin	16	12
Mometasone Furoate	Mometasone Furoate	16	13
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Famotidine	Famotidine	15	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Amoxicillin	Amoxicillin	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Alprazolam Er	Alprazolam	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Primidone	Primidone	13	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	12	suppressed
Febuxostat	Febuxostat	12	suppressed
Invokana	Canagliflozin	12	suppressed
Mounjaro	Tirzepatide	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	11
Synjardy	Empagliflozin/Metformin Hcl	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error